Florida Cancer Specialists & Research Institute Appoints Joel Grossman, MD and Maen Hussein, MD to Executive Board
Florida Cancer Specialists & Research Institute, LLC is pleased to announce the appointments of Joel Grossman, MD and Maen Hussein, MD to its Executive Board. Dr. Hussein also serves on the Finance Committee.
Fort Myers, Fla., January 15, 2024 – Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to announce the appointments of Joel Grossman, MD and Maen Hussein, MD to its Executive Board. Dr. Hussein also serves on the Finance Committee.
FCS Chief Executive Officer Nathan H. Walcker added, “Our Executive Board members have a significant impact on the direction we take and the decisions we make in this highly dynamic and rapidly changing environment. We value the expertise and insights these physicians will contribute to achieving our mission, vision and strategic priorities.”
Board-certified in medical oncology, Dr. Grossman joined FCS in 2003 and provides oncology care in Naples. Dr. Grossman serves as the Division Chief of Oncology and Hematology for the NCH Healthcare System and is actively involved in a variety of community activities. He has previously served three terms on the FCS Executive Board. He was the inaugural Chair of the Compensation Committee and currently serves on the EMR Committee.
Dr. Hussein joined FCS in 2011 and currently serves patients at FCS Brownwood and Villages Cancer Center. An active cancer researcher and advocate for the vital importance of clinical trials, Dr. Hussein has served as principal investigator on numerous clinical trials with a focus on lung cancer. His work has been published and presented in prestigious industry publications and symposiums. Dr. Hussein is the current President of the Florida Society of Clinical Oncology (FLASCO) board of directors. Additionally, he is a member of the board of directors and immediate past chair of the FCS Foundation.
“Dr. Grossman and Dr. Hussein are outstanding physicians who always strive to do more to ensure that patients have the best possible care experience,” said FCS President & Managing Physician Lucio N. Gordan, MD. “Their willingness to serve on the Executive Board is further evidence of their commitment to delivering world-class cancer care in community settings.”
For a complete list of FCS Executive Board Members, visit: https://flcancer.com/physician-leadership/
Petosemtamab and Pembrolizumab: A Promising Pair in HNSCC Treatment
July 2nd 2024In an interview, Cesar Augusto Perez, MD, delved into the findings from a phase 2 study evaluating petosemtamab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Read More
